Editor’s Note (9/19/2014): We’re pleased to share that another key step has been taken in the legislative process! Representatives Tom Reed, Dianna DeGette, and Ed Whitfield have introduced companion legislation into the House of Representatives. Read this blog to learn more!
When it comes to bills in Congress and important healthcare policy initiatives for people with diabetes, we understand that it can seem complex when trying to understand how to tackle these issues. An issue we’ve been diligently working on is making Continuous Glucose Monitoring (CGM) technology accessible for people with diabetes. We know CGM technology can transform diabetes care, and has been proven to improve glucose control – helping to prevent dangerous high and low blood sugar 1, 2– and is already covered by most private health plans. However, Medicare does not yet cover CGM, denying Americans age 65 and older access to this important technology. We’ve heard tremendous feedback from our customers and know this has been difficult for those losing access.
Over the past year, we have been collaborating with a coalition of patient advocate groups including JDRF, clinical societies and industry partners all unified behind the objective to provide access to CGM for Medicare patients. We’re pleased to report that Senate Diabetes Caucus Co-Chairs Senator Susan Collins (R-ME) and Senator Jeanne Shaheen (D-NH) have introduced bipartisan legislation that would provide Medicare coverage of CGM. For more background on the history of this initiative and how it works, visit here.
Step 1: Write your legislator and let your friends know how they can help. Find your legislator and easily send them an email here.
Step 2: Sign-up to be a JDRF Advocate to see how you can get involved with advocating for CGM coverage.
Step 3: Visit this blog in the future as we will keep our community informed on any important updates.
IMPORTANT SAFETY INFORMATION
– Medtronic Diabetes insulin infusion pumps, continuous glucose monitoring systems and associated components are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks associated with the use of these systems.
– Successful operation of the insulin infusion pumps and/or continuous glucose monitoring systems requires adequate vision and hearing to recognize alerts and alarms.
Medtronic Diabetes Insulin Infusion Pumps
– Insulin pump therapy is not recommended for individuals who are unable or unwilling to perform a minimum of four blood glucose tests per day.
– Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.
Please visit www.medtronicdiabetes.com/importantsafetyinformation for complete safety information.
1 Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320.
2 Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia. 2012;55:3155-3162.
Tags: cgm advocacy
, cgm coverage
, diabetes advocacy